Research Papers:

Integrin α6 promotes esophageal cancer metastasis and is targeted by miR-92b

Gang Ma, Chao Jing, Furong Huang, Xukun Li, Xiufeng Cao _ and Zhihua Liu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:6681-6690. https://doi.org/10.18632/oncotarget.14259

Metrics: PDF 1537 views  |   HTML 2158 views  |   ?  


Gang Ma1,*, Chao Jing1,*, Furong Huang1, Xukun Li1, Xiufeng Cao2, Zhihua Liu1

1The State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Collaborative Innovation Center for Cancer Medicine, Beijing, China

2Department of Oncological Surgery, The Affiliated Nanjing 1st Hospital, Nanjing Medical University, Nanjing, China

*These authors have contributed equally to this work

Correspondence to:

Zhihua Liu, email: [email protected]

Keywords: integrin α6, esophageal cancer, metastasis, microRNA-92b

Received: May 04, 2016     Accepted: December 12, 2016     Published: December 27, 2016


Tumor invasion and metastasis is responsible for the poor prognosis of esophageal squamous cell carcinoma (ESCC); therefore, exploring the mechanisms by which malignant cells disseminate, spread and flourish in secondary sites, as well as translating the bench results to clinical practice are in urgent need. Previous reports showed that integrin α6 increases in ESCC specimens and its dysregulated spatial localization correlates positively with the unfavorable outcome of ESCC patients. Here, we clarify that integrin α6 promotes invasion and metastasis of ESCC cells In vitro and in vivo. Mechanistically, decreased integrin α6 attenuates motility of malignant cells partially through deactivating Akt pathway, which is essential for ESCC cells motility. Moreover, integrin α6 serves as a genuine target of miR-92b in suppressing ESCC motility. Our results for the first time describe that miR-92b/integrin α6/Akt axis controls the motility of ESCC, thereby providing a promising diagnosis or therapeutic option.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14259